
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

For the month of April 2022

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant's name into English)

Australia

(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On April 6, 2022, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement which is attached hereto as [Exhibit 99.1](#), and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

MESOBLAST LIMITED

/s/ Niva Sivakumar

Niva Sivakumar
Company Secretary

Dated: April 8, 2022

INDEX TO EXHIBITS

Item

99.1 Press release of Mesoblast Ltd, dated April 6, 2022.

APPOINTMENT OF JOINT COMPANY SECRETARY

Melbourne, Australia; April 6 and New York, USA; April 6, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Paul Hughes has been appointed as Joint Company Secretary of Mesoblast Limited, joining the existing Company Secretary, Ms Niva Sivakumar. Mr Hughes and Ms Sivakumar are jointly responsible for the Company Secretary role for Mesoblast and are the persons responsible under Listing Rule 12.6 for communications with the ASX.

Ms Sivakumar was appointed as Company Secretary of Mesoblast Limited in October 2019. Mr Hughes began working with Mesoblast in February 2019 following a long career as an investment banker and corporate advisor. He has served as Mesoblast's Global Head of Corporate Communications since December 2020.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors

Paul Hughes
 T: +61 3 9639 6036
 E: investors@mesoblast.com

Media

Sumit Media
 Grant Titmus
 T: +61 419 388 161
 E: grant@sumitmedia.com.au

Rubenstein
 Nadine Woloshin
 T: +1 917-699-9456
 E: nwoloshin@rubenstein.com

Mesoblast Limited
 ABN 68 109 431 870
www.mesoblast.com

Corporate Headquarters
 Level 38
 55 Collins Street
 Melbourne 3000
 Victoria Australia
 T +61 3 9639 6036
 F +61 3 9639 6030

United States Operations
 505 Fifth Avenue
 Third Floor
 New York, NY 10017
 USA
 T +1 212 880 2060
 F +1 212 880 2061

Asia
 21 Biopolis Road
 #01-22 Nucleos (South Tower)
 SINGAPORE 138567
 T +65 6570 0635
 F +65 6570 0176